EDUCATION and TRAINING

• Ph.D. in Immunology, Shiraz University of Medical Sciences, Shiraz – Iran, (2002-Febreuary 2008)
• Medical Doctor. School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran,1991-1998.

• Selected researcher student of Shiraz University of Medical Sciences in 2004 and 2005
• Member of "Gifted Talent Office"; Shiraz University of Medical Sciences during PhD study

PUBLICATIONS & PRESENTATIONS

1. Mojtahedi Z, Omrani GR, Doroudchi M, Ghaderi A. CTLA-4 +49 A/G polymorphism is associated with predisposition to type 1 diabetes in Iranians. Diabetes Res Clin Pract 2005; 68: 111-116.

2. Mojtahedi Z, Naeimi S, Farjadian S, Omrani GR, Ghaderi A. Association of IL-18 promoter polymorphisms with predisposition to Type 1 diabetes. Diabt Med 2006 ;23(3):235-9.

3. Mojtahedi Z, Ghaderi, A. Does autoantigen adminstration inhibit recurrence of type 1 diabetes in transplanted islets?. Medical Hypotheses 2005; 64: 986-8.

4. Mojtahedi Z, Ghaderi, A. Role of interleukin-18 in allergy and autoimmunity: an explanation for the hygiene hypothesis. Medical Hypotheses 2005; 65: 305-7.

5. Mojtahedi Z. Th2-biased immune response in cervical lymph nodes: animal models of Graves’ disease might administer autoantigen to body regions where lymphatics drain to cervical lymph nodes. Medical Hypotheses. 2005;65(4):722-4.

6. Mojtahedi Z, Ahmadi SB, Razmkhah M, Azad TK, Rajaee A, Ghaderi A. Association of chemokine receptor 5 (CCR5) delta32 mutation with Behçet's disease is dependent on gender in Iranian patients. Clin Exp Rheumatol 2006;24(5 Suppl 42):S91-4.

7. Mojtahedi Z. An assumption on possible long-term side effects of CCR5 antagonists. HIV Clin Trials 2006;7(4):215-7..

8. Mojtahedi Z. Interleukin (IL)-18 may enhance Th1 response in early cancer but aggravate malignant disease in its later stages. Medical Hypotheses 2005;65(5):995-6.

9. Naeimi S, Ghiam AF, Mojtahedi Z, Dehaghani SM, Amani D, Ghaderi A. Interleukin-18 gene promoter polymorphisms and recurrent spontaneous abortion. Euro J Obstet Gynecol Reprod Biol 2006;128 (1-2):5-9..

10. Almasi SH, Erfani N, Mojthedi Z, Ghaderi A. CTLA-4 polymorphism and systemic sclerosis. Genes Immun 2006;7(5):401-6.

11. Mojtahedi Z, Clos J, Kamali-Sarvestani E. Leishmania major: Identification of developmentally regulated proteins in procyclic and metacyclic promastigotes. Exp Parasitol. 2008l;119(3):422-9.

12. Asefi V, Mojtahedi Z, Khademi B, Naeimi S, Ghaderi A. Head and neck squamous cell carcinoma (HNSCC) is not associated with interleukin-18 promoter gene polymorphisms, a case control study. JLO. In press.

Presentations:

• Mojtahedi Z, Omrani GR, Doroudchi M, Ghaderi A. CTLA-4 +49 A/G polymorphism is associated with predisposition to type 1 diabetes in Iranians The 7^th Iranian Congress of Immunology and Allergy. May, 2004, Mashhad –Iran

TRAINING AND WORKSHOP ATTENDED

Teaching:

Immunology lecturer for PhD, MSc, Medicen, Dientistry and Pharmacy students, Shiraz Medical school, Shiraz university of Medical Sciences, 2004-2006.

Techniques: 

1. Expert in cell culture.
2. Expert in several immunological based techniques including: Immunohistochemistry, ELISA, IF (ANA), Immunoblotting.
3. Expert in several molecular based techniques including PCR, RFLP, SSCP, SDS-PAGE.
4. Expert in 2-Dimensinal Electrophoresis, immunoproteome and MALDI-TOF.
5. Familiar with Bioinformatics and softwars including ImageMaster 2-D Platinum.

ONGOING RESEARCHES

Currently working as the head of Proteomics laboratory at Shiraz Institute for Cancer Research (ICR).

Current project

HER2 is a member of epidermal growth factor receptor with tyrosine kinase activity that has several functions, including the control of cellular proliferation. overexpression of HER2 present in 20%-30% of breast cancers, and that associated with poor prognosis. Expressed proteins and elicited immune response by HER2 positive and negative breast cancer patients has demonstrated some substantial differences. Proteomics- the large-scale study of proteins- has been widely used in malignant processes to find new prognostic and or therapeutic targets. The overall goals of our research projects are:

(1) identification of proteins differentially expressed in HER2 positive and negative breast cancer patients

(2) identification of proteins elicited a humoral immune response in HER2 positive breast cancer patients

(3) identification of proteins elicited a humoral immune response in HER2 negative breast cancer patients

(4) Comparing immunoproteome of HER2 positive and negative breast cancer patients.

We hope to use information gained from these studies to find out new prognostic or therapeutic targets.

Work in progress:

This project began in August 2008 and is currently in identification of proteins differentially expressed in HER2 positive and negative breast cancer patients phase.

FIELD OF INTEREST:

Cancer Immunology and Immunotherapy 

REFEREES

• Professor Abbas Ghaderi (ICR Chairman)
  Shiraz Institute for Cancer Research & Department of Immunology
  Medical School

PO BOX: 71345-1798
Shiraz - Iran
Tel/: +98-711-2303678

Fax: +98-711-2304952

E-mail: ghadria@sums.ac.ir 

• Professor Bijan Khademi

  Department of ENT

  Shiraz University of Medical Sciences

  Shiraz, Iran

  Tel: (+) 98 711 647 1476

  Fax: (+) 98 711 6471480

  Email: khademib@sums.ac.ir